Briefing documents released in advance of Thursday's meeting of the FDA's Endocrinological and Metabolic Drugs Advisory Committee (EMDAC) suggested Arena Pharmaceuticals Inc. may have allayed many of the agency's concerns about the safety of its weight loss drug Lorqess (lorcaserin).